| dc.creator | Chalkias A., Laou E., Kolonia K., Ragias D., Angelopoulou Z., Mitsiouli E., Kallemose T., Smith-Hansen L., Eugen-Olsen J., Arnaoutoglou E. | en |
| dc.date.accessioned | 2023-01-31T07:42:34Z | |
| dc.date.available | 2023-01-31T07:42:34Z | |
| dc.date.issued | 2022 | |
| dc.identifier | 10.1016/j.surg.2021.10.012 | |
| dc.identifier.issn | 00396060 | |
| dc.identifier.uri | http://hdl.handle.net/11615/72429 | |
| dc.description.abstract | Background: Patients undergoing major surgery are often at risk of developing postoperative complications. We investigated whether a preoperative marker of chronic inflammation, soluble urokinase plasminogen activator receptor, can aid in identifying patients at high risk for postoperative complications, morbidity, and mortality. Methods: In this prospective observational study (ClinicalTrials.gov identifier: NCT03851965), EDTA blood was collected from consecutive adult White patients scheduled for major noncardiac surgery with expected duration ≥2 hours under general anesthesia. Inclusion criteria were age ≥18 years and American Society of Anesthesiologists physical status I to IV. Plasma soluble urokinase plasminogen activator receptor levels were determined using the suPARnostic quick triage lateral flow assay. The primary endpoint was postoperative complications defined as presence of any complication and/or admission to intensive care unit and/or mortality within the first 90 postoperative days. Results: Preoperative soluble urokinase plasminogen activator receptor had an odds ratio of 1.50 (95% confidence interval: 1.24–1.82) for every ng/mL increase. When including age, sex, American Society of Anesthesiologists score, C-reactive protein, and grouped soluble urokinase plasminogen activator receptor in multivariate analysis, patients with soluble urokinase plasminogen activator receptor between 5.5 and 10 ng/mL had an odds ratio of 11.2 (confidence interval: 3.1–40.8) and patients with soluble urokinase plasminogen activator receptor >10 ng/mL had an odds ratio of 19.9 (95% confidence interval: 4.3–92.9) compared to patients with soluble urokinase plasminogen activator receptor ≤5.5 ng/mL, respectively. Receiver operating characteristic analysis of soluble urokinase plasminogen activator receptor showed an area under the curve of 0.82 (confidence interval: 0.72–0.91). Receiver operating characteristic analysis combining age, sex, C-reactive protein levels, and American Society of Anesthesiologists score and had an area under the curve of 0.71 (95% confidence interval: 0.61–0.82). Adding soluble urokinase plasminogen activator receptor to this model increased the area under the curve to 0.83 (95% confidence interval: 0.74–0.92) (P = .033). Conclusion: Preoperative soluble urokinase plasminogen activator receptor provided strong and independent predictive value on postoperative complications in White patients undergoing major noncardiac surgery. © 2021 Elsevier Inc. | en |
| dc.language.iso | en | en |
| dc.source | Surgery (United States) | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85118541913&doi=10.1016%2fj.surg.2021.10.012&partnerID=40&md5=0febde08fc7aecd6797fe7ce5c091538 | |
| dc.subject | C reactive protein | en |
| dc.subject | soluble urokinase plasminogen activator receptor | en |
| dc.subject | unclassified drug | en |
| dc.subject | urokinase receptor | en |
| dc.subject | biological marker | en |
| dc.subject | C reactive protein | en |
| dc.subject | urokinase receptor | en |
| dc.subject | adult | en |
| dc.subject | aged | en |
| dc.subject | area under the curve | en |
| dc.subject | Article | en |
| dc.subject | asthma | en |
| dc.subject | biochemistry | en |
| dc.subject | blood cell count | en |
| dc.subject | blood sampling | en |
| dc.subject | centrifugation | en |
| dc.subject | cerebrovascular accident | en |
| dc.subject | Charlson Comorbidity Index | en |
| dc.subject | chronic inflammation | en |
| dc.subject | chronic obstructive lung disease | en |
| dc.subject | clinical outcome | en |
| dc.subject | clinical trial | en |
| dc.subject | controlled study | en |
| dc.subject | coronary artery disease | en |
| dc.subject | creatinine blood level | en |
| dc.subject | data analysis | en |
| dc.subject | diabetes mellitus | en |
| dc.subject | diagnostic test accuracy study | en |
| dc.subject | female | en |
| dc.subject | general anesthesia | en |
| dc.subject | heart surgery | en |
| dc.subject | human | en |
| dc.subject | hypercholesterolemia | en |
| dc.subject | hypertension | en |
| dc.subject | information processing | en |
| dc.subject | intensive care unit | en |
| dc.subject | laboratory test | en |
| dc.subject | lateral flow immunochromatography | en |
| dc.subject | male | en |
| dc.subject | monitoring | en |
| dc.subject | morbidity | en |
| dc.subject | mortality | en |
| dc.subject | multivariate analysis | en |
| dc.subject | observational study | en |
| dc.subject | postoperative complication | en |
| dc.subject | prediction | en |
| dc.subject | predictive value | en |
| dc.subject | prospective study | en |
| dc.subject | receiver operating characteristic | en |
| dc.subject | risk | en |
| dc.subject | risk assessment | en |
| dc.subject | sampling | en |
| dc.subject | sensitivity and specificity | en |
| dc.subject | survival | en |
| dc.subject | adolescent | en |
| dc.subject | metabolism | en |
| dc.subject | postoperative complication | en |
| dc.subject | prognosis | en |
| dc.subject | Adolescent | en |
| dc.subject | Adult | en |
| dc.subject | Biomarkers | en |
| dc.subject | C-Reactive Protein | en |
| dc.subject | Humans | en |
| dc.subject | Postoperative Complications | en |
| dc.subject | Prognosis | en |
| dc.subject | Receptors, Urokinase Plasminogen Activator | en |
| dc.subject | ROC Curve | en |
| dc.subject | Elsevier Inc. | en |
| dc.title | Elevated preoperative suPAR is a strong and independent risk marker for postoperative complications in patients undergoing major noncardiac surgery (SPARSE) | en |
| dc.type | journalArticle | en |